Infinity Pharmaceuticals Inc. (NASDAQ:INFI) Given Consensus Rating of “Hold” by Brokerages

Infinity Pharmaceuticals Inc. (NASDAQ:INFI) has earned a consensus rating of “Hold” from the eight analysts that are covering the stock, Marketbeat reports. Two equities research analysts have rated the stock with a sell rating, three have issued a hold rating and three have issued a buy rating on the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $3.00.

A number of brokerages recently issued reports on INFI. Zacks Investment Research upgraded shares of Infinity Pharmaceuticals from a “hold” rating to a “buy” rating and set a $2.00 target price for the company in a research report on Thursday, March 28th. CIBC began coverage on shares of Infinity Pharmaceuticals in a research report on Thursday. They set an “outperform” rating for the company. Oppenheimer began coverage on shares of Infinity Pharmaceuticals in a research report on Thursday. They set an “outperform” rating and a $3.00 target price for the company. Finally, ValuEngine cut shares of Infinity Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, May 1st.

Shares of Infinity Pharmaceuticals stock opened at $1.74 on Friday. The firm has a market cap of $95.64 million, a PE ratio of -8.70 and a beta of 1.95. The stock’s 50-day moving average price is $1.54. Infinity Pharmaceuticals has a 12-month low of $1.00 and a 12-month high of $2.92.

Infinity Pharmaceuticals (NASDAQ:INFI) last announced its earnings results on Tuesday, May 7th. The biotechnology company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.19). The company had revenue of $2.14 million for the quarter, compared to analyst estimates of $10.07 million. Equities research analysts expect that Infinity Pharmaceuticals will post -0.74 EPS for the current fiscal year.

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Community Bank N.A. increased its position in Infinity Pharmaceuticals by 71.4% in the 1st quarter. Community Bank N.A. now owns 24,000 shares of the biotechnology company’s stock valued at $45,000 after acquiring an additional 10,000 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. increased its position in Infinity Pharmaceuticals by 54.2% in the 1st quarter. Connor Clark & Lunn Investment Management Ltd. now owns 45,232 shares of the biotechnology company’s stock valued at $85,000 after acquiring an additional 15,908 shares in the last quarter. Two Sigma Investments LP increased its position in Infinity Pharmaceuticals by 29.4% in the 4th quarter. Two Sigma Investments LP now owns 91,296 shares of the biotechnology company’s stock valued at $108,000 after acquiring an additional 20,721 shares in the last quarter. Bank of New York Mellon Corp increased its position in Infinity Pharmaceuticals by 73.6% in the 4th quarter. Bank of New York Mellon Corp now owns 72,256 shares of the biotechnology company’s stock valued at $85,000 after acquiring an additional 30,622 shares in the last quarter. Finally, Two Sigma Securities LLC acquired a new stake in Infinity Pharmaceuticals in the 4th quarter valued at about $40,000. Hedge funds and other institutional investors own 54.33% of the company’s stock.

Infinity Pharmaceuticals Company Profile

Infinity Pharmaceuticals, Inc, a biopharmaceutical company, develops medicines for people with cancer in the United States. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma), which is in Phase 1/1b clinical study.

Recommended Story: Futures Contract

Analyst Recommendations for Infinity Pharmaceuticals (NASDAQ:INFI)

Receive News & Ratings for Infinity Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Infinity Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.